Login to Your Account

Pharma: Other News To Note

Monday, July 15, 2013
• Actavis Inc., of Parsippany, N.J., said it received approval from the FDA on its abbreviated new drug application for oxymorphone hydrochloride extended-release tablets at dosages of 5 mg, 10 mg, 20 mg, 30 mg and 40 mg.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription